Brokers Set Expectations for MannKind FY2026 Earnings

MannKind Co. (NASDAQ:MNKD) – Cantor Fitzgerald issued their FY2026 EPS estimates for MannKind in a research report issued on Monday, June 9th. Cantor Fitzgerald analyst O. Brayer anticipates that the biopharmaceutical company will post earnings of $0.24 per share for the year. The consensus estimate for MannKind’s current full-year earnings is $0.10 per share.

Several other equities analysts have also recently weighed in on the company. Wedbush reiterated an “outperform” rating and set a $11.00 price objective on shares of MannKind in a report on Thursday, February 27th. Wall Street Zen lowered shares of MannKind from a “buy” rating to a “hold” rating in a research note on Friday, June 6th. Finally, Mizuho initiated coverage on shares of MannKind in a research report on Thursday, April 10th. They set an “outperform” rating and a $12.00 price objective for the company. One research analyst has rated the stock with a hold rating, six have issued a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, MannKind presently has an average rating of “Buy” and a consensus target price of $10.00.

MannKind Trading Down 10.3%

MNKD stock opened at $3.92 on Tuesday. MannKind has a 1-year low of $3.89 and a 1-year high of $7.63. The firm has a market cap of $1.19 billion, a PE ratio of 56.00 and a beta of 1.02. The business’s 50-day moving average price is $4.54 and its two-hundred day moving average price is $5.42.

MannKind (NASDAQ:MNKD) last announced its quarterly earnings results on Thursday, May 8th. The biopharmaceutical company reported $0.04 earnings per share for the quarter, topping analysts’ consensus estimates of $0.03 by $0.01. MannKind had a net margin of 8.07% and a negative return on equity of 17.74%. The company had revenue of $78.35 million for the quarter, compared to analysts’ expectations of $75.86 million. During the same period last year, the firm posted $0.05 earnings per share. The business’s quarterly revenue was up 18.1% compared to the same quarter last year.

Insider Activity

In other MannKind news, EVP David Thomson sold 32,179 shares of the business’s stock in a transaction that occurred on Tuesday, May 13th. The stock was sold at an average price of $4.68, for a total transaction of $150,597.72. Following the transaction, the executive vice president now owns 772,427 shares of the company’s stock, valued at $3,614,958.36. The trade was a 4.00% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Steven B. Binder sold 80,144 shares of the company’s stock in a transaction that occurred on Tuesday, May 13th. The stock was sold at an average price of $4.69, for a total value of $375,875.36. Following the sale, the director now owns 1,006,611 shares in the company, valued at approximately $4,721,005.59. This represents a 7.37% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 190,831 shares of company stock worth $846,298 over the last ninety days. Insiders own 2.70% of the company’s stock.

Institutional Investors Weigh In On MannKind

Several large investors have recently made changes to their positions in MNKD. Barclays PLC raised its position in MannKind by 186.0% during the third quarter. Barclays PLC now owns 519,865 shares of the biopharmaceutical company’s stock worth $3,271,000 after acquiring an additional 338,121 shares in the last quarter. Victory Capital Management Inc. increased its stake in shares of MannKind by 358.6% during the 4th quarter. Victory Capital Management Inc. now owns 219,367 shares of the biopharmaceutical company’s stock worth $1,411,000 after purchasing an additional 171,537 shares during the last quarter. Arrowstreet Capital Limited Partnership raised its holdings in shares of MannKind by 275.9% in the 4th quarter. Arrowstreet Capital Limited Partnership now owns 4,887,609 shares of the biopharmaceutical company’s stock valued at $31,427,000 after purchasing an additional 3,587,484 shares during the period. Charles Schwab Investment Management Inc. raised its holdings in shares of MannKind by 2.0% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 2,270,106 shares of the biopharmaceutical company’s stock valued at $14,597,000 after purchasing an additional 45,277 shares during the period. Finally, Proficio Capital Partners LLC acquired a new stake in MannKind in the 4th quarter valued at about $70,000. Institutional investors and hedge funds own 49.55% of the company’s stock.

MannKind Company Profile

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults.